The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report

Abstract Background Major depressive disorder (MDD) patients not responding to two or more different antidepressant treatments are currently considered to suffer from treatment resistant depression (TRD). Recently, intranasal esketamine has been approved by both the American Food and Drug Administra...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Marcatili Matteo, Pellicioli Cristian, Maggioni Laura, Motta Federico, Redaelli Chiara, Ghelfi Lorenzo, Krivosova Michaela, Matteo Sibilla, Nava Roberto, Colmegna Fabrizia, Dakanalis Antonios, Caldiroli Alice, Capuzzi Enrico, Benatti Beatrice, Bertola Francesca, Villa Nicoletta, Piperno Alberto, Ippolito Silvia, Clerici Massimo
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2021-09-01
Serie:	Annals of General Psychiatry
Soggetti:	Treatment resistant depression TRD Obsessive–compulsive disorder OCD Esketamine Ketamine
Accesso online:	https://doi.org/10.1186/s12991-021-00365-z
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!